Cogent Biosciences, Inc.
COGT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001622229
Insider trades, last 90 days
0 buys · 1 sell
- Sold $1.69M
- Open-market purchases (P) and sales (S), counted by Form 4 filing.
13F holders, Q2 2026
335
- +14 vs. Q1 2026
- Total value $7.82B
Superinvestors holding COGT
1
- At the end of Q2 2026
Price chart
Latest insider trades
View all: Latest insider tradesOpen-market purchases and sales by COGT insiders, newest first.
| Filed (ET) | Trade date | Insider | Transaction | Shares | Avg price | Value | Shares after | Holding change | Filing |
|---|---|---|---|---|---|---|---|---|---|
| Aug 31, 20265:01 PM ET | Aug 27, 2026 | Morris ArleneDirector | SSaleCommon Stock | −45.51K | $37.1236 | −$1.69M | 0 | −100.0% | SEC10b5-1 |
| Mar 31, 2026 | Mar 31, 2026 | Fairmount Funds Management LLCDirector | SSaleCommon Stock | −7M | $34.66 | −$242.62M | 5.5M | −56.0% | SEC |
| Jan 22, 2026 | Jan 22, 2026 | Fairmount Funds Management LLCDirector | SSaleCommon Stock | −3.5M | $36.40 | −$127.4M | 5.5M | −38.9% | SEC |
| Dec 30, 2025 | Dec 26, 2025 | Kearns EvanChief Legal Officer | SSaleCommon Stock | −65K | $38.70 | −$2.52M | 109.4K | −37.3% | SEC |
| Dec 30, 2025 | Dec 26, 2025 | Green John L.Chief Financial Officer | SSaleCommon Stock | −77K | $38.68 | −$2.98M | 131.83K | −36.9% | SEC |
Top 5 13F holders, Q2 2026
View all: Top 5 13F holders, Q2 2026The largest institutional positions in COGT at the end of Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 25,681,174 | $995.76M | 0.04% | +2,558,426+11.1% | Added |
| BlackRock, Inc. | 17,352,646 | $671.55M | 0.01% | +1,307,632+8.1% | Added |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 8,072,411 | $312.4M | 0.01% | +739,078+10.1% | Added |
| VANGUARD CAPITAL MANAGEMENT LLC | 7,412,330 | $286.86M | 0.01% | +517,371+7.5% | Added |
| STATE STREET CORP | 6,964,919 | $269.54M | 0.01% | +1,301,376+23.0% | Added |